2m 2m 2m 2m 2m 2m 2m
KALVISTA PHARMAC (KALV)
NASDAQ
$26.95+$0.006 (+0.02%)
Price as of Jun 03, 2026 7:12 PM EDT- $1.4BMarket Cap
- 101.80%1-Year Change
- BiotechnologyIndustry
KALVISTA PHARMAC (KALV)
$26.95+$0.006 (+0.02%)
Annual
Quarterly
12/31/2025 | 04/30/2024 | 04/30/2023 | 04/30/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 49.1M +477.39% | 8.5M -46.20% | 15.8M +24.51% | 12.7M 0.00% | |
Cost of Revenue | 3.1M N/A | N/A N/A | N/A N/A | N/A N/A | |
Gross Profit | 5.0M -41.18% | 8.5M -46.20% | 15.8M +24.51% | 12.7M 0.00% | |
Sales and Marketing Expense | 124.7M N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -33.4M -61.27% | -86.2M +7.34% | -80.3M +14.41% | -70.2M +69.95% | |
Depreciation and Amortization Expense | 969,000 +18.75% | 816,000 +13.65% | 718,000 +27.30% | 564,000 +5.03% | |
Total Operating Expenses | 161.1M +14.72% | 140.4M +26.67% | 110.9M +14.76% | 96.6M +66.80% | |
Operating Profit | -109.5M -22.03% | -140.4M +26.67% | -110.9M +14.76% | -96.6M +66.80% | |
Interest Income | 5.8M +48.59% | 3.9M +74.55% | 2.2M +104.77% | 1.1M +20.71% | |
Interest Expense | -1.4M N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | 4.4M +12.65% | 3.9M +74.55% | 2.2M +104.77% | 1.1M +20.71% | |
Total Nonoperating Income and Expense | 1.5M -89.28% | 13.8M -23.17% | 18.0M +25.85% | 14.3M +22.22% | |
Income before Taxes | -109.5M -13.54% | -126.6M +36.31% | -92.9M +12.83% | -82.3M +78.05% | |
Income Taxes | -1.0M N/A | 0 N/A | 0 N/A | 0 N/A | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -109.5M -13.54% | -126.6M +36.31% | -92.9M +12.83% | -82.3M +78.05% | |
Net Income from Continuing Operations Applicable to Common | -109.5M -13.54% | -126.6M +36.31% | -92.9M +12.83% | -82.3M +78.05% | |
Basic EPS and Net Income | -2.03 -40.99% | -3.44 +3.30% | -3.33 -0.89% | -3.36 +38.84% | |
Diluted EPS and Net Income | -2.03 -40.99% | -3.44 +3.30% | -3.33 -0.89% | -3.36 +38.84% | |
Basic Weighted Average Shares | 53.9M +46.44% | 36.8M +31.89% | 27.9M +13.97% | 24.5M +28.17% | |
Diluted Weighted Average Shares | 53.9M +46.44% | 36.8M +31.89% | 27.9M +13.97% | 24.5M +28.17% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 229.3M +621.45% | 31.8M -43.47% | 56.2M +82.99% | 30.7M -39.26% | |
Short-Term Investments | 70.9M -60.32% | 178.6M +91.77% | 93.1M -31.25% | 135.5M -31.70% | |
Cash and Cash Equivalents and Short-Term Investments | 300.2M +42.69% | 210.4M +40.85% | 149.4M -10.12% | 166.2M -33.23% | |
Total Current Assets | 320.1M +41.85% | 225.7M +30.97% | 172.3M -11.01% | 193.6M -26.72% | |
Accumulated Depreciation | 5.4M +44.77% | 3.7M +25.49% | 3.0M +22.28% | 2.4M +15.80% | |
Property and Plant and Equipment and Net | 3.0M +36.24% | 2.2M -24.46% | 2.9M +35.35% | 2.2M +21.61% | |
Total Long-Term Assets | 2.4M +317.81% | 567,000 +434.91% | 106,000 -45.08% | 193,000 -3.50% | |
Total Assets | 335.4M +42.47% | 235.4M +28.49% | 183.2M -10.14% | 203.9M -25.05% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | 700,000 N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Current Liabilities | 57.4M +151.48% | 22.8M +51.72% | 15.0M +29.85% | 11.6M +18.44% | |
Total Long-Term Debt | 139.2M N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Long-Term Liabilities | 22.4M +273.08% | 6.0M -15.82% | 7.1M -0.92% | 7.2M +42.91% | |
Total Liabilities | 338.1M +1,073.01% | 28.8M +29.96% | 22.2M +18.04% | 18.8M +26.77% | |
Retained Earnings | -762.7M +62.37% | -469.7M +36.91% | -343.1M +37.14% | -250.2M +49.06% | |
Total Stockholders Equity | -2.7M -101.31% | 206.6M +28.29% | 161.0M -13.00% | 185.1M -28.03% | |
Total Shares Outstanding | 50.9M +19.70% | 42.5M +24.44% | 34.2M +39.19% | 24.6M +0.52% | |
Cash Flow | |||||
Cash from Operating Activities | -81.6M -8.53% | -89.2M +18.56% | -75.3M -3.68% | -78.1M +158.97% | |
Capital Expenditures | 1.7M +3,964.29% | 42,000 -96.49% | 1.2M +28.46% | 931,000 +1,035.37% | |
Cash from Investing Activities | 18.7M +122.05% | -84.7M -304.56% | 41.4M -28.42% | 57.9M +139.19% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 162.6M +7.91% | 150.7M +159.33% | 58.1M +3,575.90% | 1.6M -99.25% | |
Financials Ratio | |||||
Gross Margin | 93.72% N/A | N/A N/A | N/A N/A | N/A N/A | |
Operating Margin | -223.11% -86.50% | -1,652.29% +135.47% | -701.72% -7.83% | -761.33% +66.80% | |
Return on Assets | -38.37% -36.59% | -60.51% +26.05% | -48.00% +38.72% | -34.60% +36.39% | |
Return on Equity | -107.42% +55.90% | -68.90% +28.34% | -53.69% +44.19% | -37.23% +37.26% | |
Revenue Growth | 477.39% +1,133.25% | -46.20% -288.52% | 24.51% N/A | 0.00% N/A | |
Current Ratio | 5.58 -43.59% | 9.90 -13.68% | 11.46 -31.47% | 16.73 -38.13% | |
Cash Ratio | 4.00 +186.88% | 1.39 -62.74% | 3.74 +40.92% | 2.65 -48.71% | |
Debt-to-Equity Ratio | -51.61 N/A | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | 0.42 N/A | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow